Publication:
Factors Affecting Survival in Retroperitoneal Sarcomas Treated with Upfront Surgery: A Real-World Study by Turkish Oncology Group

Simple item page
dc.contributor.authorAKIN TELLİ, TUĞBA
dc.contributor.authorsAkagunduz, Baran; Telli, Tugba Akin; Yildirim, Hasan Cagri; Goksu, Sema Sezgin; Demir, Nazan; Hafizoglu, Emre; Ozer, Muhammet; Cevik, Gokcen Tugba; Sakin, Abdullah; Aydin, Sabin Goktas; Samanci, Nilay Sengul; Ozyurt, Neslihan; Atci, Muhammed Mustafa; Ayhan, Murat; Turan, Merve; Sariyar, Nisanur; Karacin, Cengiz; Kilickap, Saadettin; Paydas, Semra; Dogan, Mutlu
dc.date.accessioned2022-03-12T22:59:13Z
dc.date.available2022-03-12T22:59:13Z
dc.date.issued2021
dc.description.abstractRetroperitoneal sarcomas (RPS) account for approximately 15% of all soft tissue sarcomas (STS) and encompass a heterogeneous group of tumors with limited multimodality treatment options. Surgical resection with negative margins remains the standard primary treatment for patients with localized RPS. In this multicenter study, we aimed to demonstrate the real-world data on factors affecting survival in RPS treated with upfront surgery. We included a total of 197 patients who underwent curative-intent resection of a primary non-metastatic RPS between 2000-2020 at ten experienced medical oncology departments in Turkey. The median follow-up was 33 months. The median age of patients was 53 years, 57.4% of patients were female. Univariate analysis revealed that; tumor size, grade, necrosis, resection margin status, were factors affecting recurrence-free survival (RFS) (p= 0.002, p= 0.044, p= 0,024, p= 0.003 respectively). Age, tumor size, stage, resection margin status were factors affecting overall survival (OS) (p= 0.038, p= 0.001, p= 0.032, p< 0.001, respectively). In multivariate analysis, tumor size and resection margin status were independent factors affecting RFS and OS (all p-values < 0.05). Our study demonstrated that tumor size, and resection margin status were the main factors affecting survival in resected RFS. In comparison, adjuvant chemotherapy (CT), radiotherapy (RT), or multimodality treatment did not show OS and RFS advantages. We believe that advances in the molecular characterization of these tumors might help clinicians to detect the best candidates for adjuvant therapies in RPS.
dc.identifier.doi10.4999/uhod.215190
dc.identifier.issn1306-133X
dc.identifier.urihttps://hdl.handle.net/11424/237286
dc.identifier.wosWOS:000641690900004
dc.language.isoeng
dc.publisherAKAD DOKTORLAR YAYINEVI
dc.relation.ispartofUHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectSurvival
dc.subjectRetroperitoneal sarcoma
dc.subjectAdjuvant chemotherapy
dc.subjectAdjuvant radiotherapy
dc.subjectSurgery
dc.subjectSOFT-TISSUE SARCOMA
dc.subjectLONG-TERM SURVIVAL
dc.subjectPROGNOSTIC-FACTORS
dc.subjectADJUVANT CHEMOTHERAPY
dc.subjectMANAGEMENT
dc.subjectRECURRENCE
dc.subjectRESECTION
dc.subjectRADIOTHERAPY
dc.titleFactors Affecting Survival in Retroperitoneal Sarcomas Treated with Upfront Surgery: A Real-World Study by Turkish Oncology Group
dc.typearticle
dspace.entity.typePublication
local.avesis.iddae41c02-1e6a-4a0a-9139-6294a23fc7b7
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.journal.numberofpages7
oaire.citation.endPage98
oaire.citation.issue2
oaire.citation.startPage92
oaire.citation.titleUHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
oaire.citation.volume31
relation.isAuthorOfPublication634579fc-78dd-43c6-b231-31cf08aea852
relation.isAuthorOfPublication.latestForDiscovery634579fc-78dd-43c6-b231-31cf08aea852

Files

Collections

Research Outputs